These options vest quarterly over two years beginning June 13, 2013.
These options vest as follows: fifty percent (50%) on the date of issuance of the CE Mark certification for Neutrolin in Europe, if the CE Mark approval is obtained on or before June 30, 2013, and (b) fifty percent (50%) on December 31, 2013.
The reporting person beneficially owns these securities through Wade Capital Corporation (an entity for which he has voting and investment control).
The options vest in full on the first anniversary of the date of grant.
The options vest ratably, one-third of which will vest on each of the grant date, the first anniversary and the second anniversary thereof.
(Right to buy Common Stock, $0.001 par value per share)
The warrants were issued as part of the Company's initial public offering in March 2010 and were exercisable beginning six months after the effective date of the Company's registration statement related thereto.
This report does not reflect 20,000 shares underlying a warrant which warrant was incorrectly reported as being owned by the reporting person's wife in a Form 3 filed on August 15, 2011.
The above information was disclosed in a filing to the SEC. To see this filing in its entirety, click here.
To receive a free e-mail notification whenever CorMedix Inc makes a similar move, sign up!
Other recent filings from the company include the following:
Prospectus [Rule 424(b)(5)] - March 6, 2014
Cormedix Inc. Announces Registered Direct Offering - March 5, 2014
CorMedix Inc just filed a General Statement of acquisition of beneficial ownership - March 5, 2014